Outlook Therapeutics® Doses First Subject in NORSE EIGHT
Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve FDA approval for the first ophthalmic formulation of bevacizumab…
Where health news comes full circle!